GlassScriptPhysician profile
Cora Tasaki
NPI 1770760662
$1,730.45
in general payments reported to CMS, 2019-2025
20 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.59 · 2020: $51.31 · 2021: $186 · 2022: $196 · 2023: $597 · 2024: $502 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $794.66 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $137.61 | 2019-2024 | Austedo Xr |
| Alnylam Pharmaceuticals INC. | $124.17 | 2023 | Amvuttra |
| Neurocrine Biosciences, INC. | $120.19 | 2024 | Ingrezza |
| Neurelis, INC. | $95.49 | 2023 | Valtoco |
| Amgen INC. | $88.01 | 2020-2021 | |
| Eisai INC. | $54.45 | 2024-2025 | |
| Greenwich Biosciences, INC. | $49.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.05 | 2022-2023 | Andexxa |
| Allergan, INC. | $33.30 | 2020 | |
| Jazz Pharmaceuticals INC. | $29.22 | 2022 | |
| Novocure INC. | $24.06 | 2024 | Optune |
| Otsuka America Pharmaceutical, INC. | $21.58 | 2023 | Rexulti |
| Ucb, INC. | $20.08 | 2023 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $19.01 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $18.75 | 2022 | |
| Argenx US, INC. | $16.22 | 2024 | Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $15.26 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $15.20 | 2021 | |
| Acadia Pharmaceuticals INC | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cora Tasaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.